Early initiation of enzyme replacement therapy in classical Fabry disease normalizes biomarkers in clinically asymptomatic pediatric patients
Amy Kritzer(Boston Children's Hospital), Olaf A. Bodamer(Broad Institute), Aishwarya Siddharth(Boston Children's Hospital), Kate Leestma(Boston Children's Hospital)
Cited by 12
Related Papers
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
|New England Journal of Medicine|2019|823
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|535
Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism–dystonia
|Nature Communications|2016|326
Phenylketonuria Scientific Review Conference: State of the science and future research needs
|Molecular Genetics and Metabolism|2014|271
Kabuki syndrome: international consensus diagnostic criteria
|Journal of Medical Genetics|2018|251